Hua T, Gao Y, Zhang R, Wei Y, et al. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings. BMC Cancer 2022;22:1022.
PMID: 36171546